PURPOSE: The aim of this study was to evaluate the effect of different clinical covariates on tacrolimus dose requirements in adult kidney transplant patients with a specific focus on drug interactions. PATIENTS: Tacrolimus dosing requirement, normalized by drug levels and expressed as the concentration/dose (C/D) ratio as a surrogate index of tacrolimus bioavailability, was employed to identify four categories of tacrolimus dosing requirement, namely, very high, high, small, and very-small, in very fast, fast, slow, and very slow metabolizers, respectively. Steroid weight-based doses were analyzed instead of fixed doses, and genetic analysis of cytochrome P450 (CYP) 3A5*1/*3 and multi-drug resistance 1 (MDR1) C3435T and C1236T polymorphisms were performed RESULTS: Multivariate analysis on 450 adult transplant patients identified six risk factors for being slow metabolizers and therefore requiring small tacrolimus doses: male sex (OR 1.615, p = 0.020); age >60 years (OR 2.456, p = 0.0005); body mass index ≥ 25 (OR 1.546, p = 0.046), hepatitis C virus positivity (OR 2.800, p = 0.0004); low steroid dose <0.06 mg/kg (OR 3.101, p < 0.0001). Patients with a small tacrolimus requirement were at increased risk for multiple infections (OR 1.533, p = 0.0008) and higher systolic blood pressure (OR 1.385, p = 0.022) and showed a significant association with the CYP3A5*3/*3 genotype adjusted by MDR1 polymorphisms C3435T and C1236T (OR 8.104, p = 0.0001). CONCLUSIONS: Our results demonstrate the importance of the interaction among genetic and clinical factors in conditioning tacrolimus disposition, with corticosteroid weight-based dose being the only modifiable risk factor for tacrolimus requirement. As the tacrolimus dosing requirement increases with increasing tacrolimus clearance through concomitant steroid use, undesirable changes in tacrolimus levels may occur when steroid doses are tapered, predominantly in slow metabolizers. This often neglected drug interaction has to be monitored to optimize tacrolimus exposure in kidney transplant patients.
PURPOSE: The aim of this study was to evaluate the effect of different clinical covariates on tacrolimus dose requirements in adult kidney transplant patients with a specific focus on drug interactions. PATIENTS: Tacrolimus dosing requirement, normalized by drug levels and expressed as the concentration/dose (C/D) ratio as a surrogate index of tacrolimus bioavailability, was employed to identify four categories of tacrolimus dosing requirement, namely, very high, high, small, and very-small, in very fast, fast, slow, and very slow metabolizers, respectively. Steroid weight-based doses were analyzed instead of fixed doses, and genetic analysis of cytochrome P450 (CYP) 3A5*1/*3 and multi-drug resistance 1 (MDR1) C3435T and C1236T polymorphisms were performed RESULTS: Multivariate analysis on 450 adult transplant patients identified six risk factors for being slow metabolizers and therefore requiring small tacrolimus doses: male sex (OR 1.615, p = 0.020); age >60 years (OR 2.456, p = 0.0005); body mass index ≥ 25 (OR 1.546, p = 0.046), hepatitis C virus positivity (OR 2.800, p = 0.0004); low steroid dose <0.06 mg/kg (OR 3.101, p < 0.0001). Patients with a small tacrolimus requirement were at increased risk for multiple infections (OR 1.533, p = 0.0008) and higher systolic blood pressure (OR 1.385, p = 0.022) and showed a significant association with the CYP3A5*3/*3 genotype adjusted by MDR1 polymorphisms C3435T and C1236T (OR 8.104, p = 0.0001). CONCLUSIONS: Our results demonstrate the importance of the interaction among genetic and clinical factors in conditioning tacrolimus disposition, with corticosteroid weight-based dose being the only modifiable risk factor for tacrolimus requirement. As the tacrolimus dosing requirement increases with increasing tacrolimus clearance through concomitant steroid use, undesirable changes in tacrolimus levels may occur when steroid doses are tapered, predominantly in slow metabolizers. This often neglected drug interaction has to be monitored to optimize tacrolimus exposure in kidney transplant patients.
Authors: Sung-In Park; Claudia R Felipe; Paula G Pinheiro-Machado; Riberto Garcia; Fernanda B Fernandes; Dulce E Casarini; Helio Tedesco-Silva; Jose O Medina-Pestana Journal: Fundam Clin Pharmacol Date: 2009-02 Impact factor: 2.748
Authors: C M O'Seaghdha; R McQuillan; A M Moran; P Lavin; A Dorman; P O'Kelly; D M Mohan; P Little; D P Hickey; P J Conlon Journal: Clin Transplant Date: 2009 Aug-Sep Impact factor: 2.863
Authors: Elly M van Duijnhoven; Johannes M M Boots; Maarten H L Christiaans; Leo M L Stolk; Nasrullah A Undre; Johannes P van Hooff Journal: Transpl Int Date: 2003-06-24 Impact factor: 3.782
Authors: Alex Ganetsky; Todd A Miano; Mitchell E Hughes; Robert H Vonderheide; David L Porter; Ran Reshef Journal: J Antimicrob Chemother Date: 2015-04-16 Impact factor: 5.790
Authors: Diego Alberto C Cusinato; Riccardo Lacchini; Elen A Romao; Miguel Moysés-Neto; Eduardo B Coelho Journal: Br J Clin Pharmacol Date: 2014-08 Impact factor: 4.335
Authors: John R Lee; Thangamani Muthukumar; Darshana Dadhania; Ying Taur; Robert R Jenq; Nora C Toussaint; Lilan Ling; Eric Pamer; Manikkam Suthanthiran Journal: PLoS One Date: 2015-03-27 Impact factor: 3.240
Authors: Gerold Thölking; Christian Fortmann; Raphael Koch; Hans Ulrich Gerth; Dirk Pabst; Hermann Pavenstädt; Iyad Kabar; Anna Hüsing; Heiner Wolters; Stefan Reuter; Barbara Suwelack Journal: PLoS One Date: 2014-10-23 Impact factor: 3.240